Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients

Abstract

The humoral response of kidney transplant recipients (KTR) to the mRNA vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is generally poor. We evaluated the booster effect of the third dose (D3) of two SARS-CoV-2 mRNA vaccines 6 months after the second dose (D2) in Japanese KTR. The anti-spike (anti-S) antibody titer 1 and 3 months after the D3 was evaluated in 82 Japanese KTR. The primary endpoint was the seropositivity rate, and factors associated with the lack of a response were evaluated in a logistic regression model. Overall, the anti-S antibody seropositivity rate 1 and 3 months after the D3 was 74.7% and 76.0%. The anti-S antibody titers after the first and second doses were higher in patients vaccinated with the mRNA-1273 than with the BNT162b2 vaccine. Among the 38 KTR who were seronegative 5 months after the D2, 18 (47.4%) became seropositive following the D3. Factors associated with a non-response were mycophenolic acid dose, post-transplant duration, hemoglobin, and lymphocyte count. A humoral response 1 and 3 months after the D3 was obtained in ~ 75% of KTR, but 20% were non-responders. Additional studies are needed to clarify the factors hindering a vaccine response.

Figure 1

Study population.

Figure 2

Violin plot of anti-S SARS-CoV-2 IgG antibody titers. Anti-S SARS-CoV-2 IgG antibody titers at 1 month and 3 months. The anti-S antibody titers at 1 month were higher than those at 3 months (p < 0.0001).

Figure 3

Comparison of anti-S SARS-CoV-2 IgG antibody titers by vaccine type (BNT162b2 or mRNA-1273) at the 1st and 2nd vaccinations. Significantly higher anti-S SARS-CoV-2 IgG antibody titers were measured when the 1st and 2nd vaccinations were mRNA-1273 rather than BNT162b2.